Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody

Gianluca Moroncini, Michela Mangieri, Michela Morbin, Giulia Mazzoleni, Bernardino Ghetti, Armando Gabrielli, Robert Anthony Williamson, Giorgio Giaccone, Fabrizio Tagliavini

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Prion diseases are characterized by the accumulation in the brain of abnormal conformers (PrPSc) of the cellular prion protein (PrPC). PrPSc immunohistochemistry, currently based on antibodies non-distinguishing between PrPC and PrPSc, requires pre-treatments of histological sections to eliminate PrPC and to denature PrPSc. We employed the PrPSc-specific antibody 89-112 PrP motif-grafted IgG on mildly fixed, untreated brain sections from several cases of human prion diseases. The results confirmed specific binding of IgG 89-112 to a structural determinant found exclusively on native disease-associated PrP conformations and lost following tissue denaturation or cross-linking fixation. Importantly, IgG 89-112 demonstrated no reactivity with normal brain tissue or with amyloid deposits in Alzheimer disease brain sections. Thus, immunohistochemical detection of native PrPSc deposits was obtained by means of a PrPSc-specific antibody. Such unique reagent may have many applications in the study of prion biology and in the diagnosis and prevention of prion diseases.

Original languageEnglish
Pages (from-to)717-724
Number of pages8
JournalNeurobiology of Disease
Volume23
Issue number3
DOIs
StatePublished - Sep 2006

Fingerprint

Prion Diseases
Antibodies
Immunoglobulin G
Brain
Prions
Amyloid Plaques
Alzheimer Disease
Immunohistochemistry
Prion Proteins
Therapeutics

ASJC Scopus subject areas

  • Neurology

Cite this

Moroncini, G., Mangieri, M., Morbin, M., Mazzoleni, G., Ghetti, B., Gabrielli, A., ... Tagliavini, F. (2006). Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. Neurobiology of Disease, 23(3), 717-724. https://doi.org/10.1016/j.nbd.2006.06.008

Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. / Moroncini, Gianluca; Mangieri, Michela; Morbin, Michela; Mazzoleni, Giulia; Ghetti, Bernardino; Gabrielli, Armando; Williamson, Robert Anthony; Giaccone, Giorgio; Tagliavini, Fabrizio.

In: Neurobiology of Disease, Vol. 23, No. 3, 09.2006, p. 717-724.

Research output: Contribution to journalArticle

Moroncini, G, Mangieri, M, Morbin, M, Mazzoleni, G, Ghetti, B, Gabrielli, A, Williamson, RA, Giaccone, G & Tagliavini, F 2006, 'Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody', Neurobiology of Disease, vol. 23, no. 3, pp. 717-724. https://doi.org/10.1016/j.nbd.2006.06.008
Moroncini, Gianluca ; Mangieri, Michela ; Morbin, Michela ; Mazzoleni, Giulia ; Ghetti, Bernardino ; Gabrielli, Armando ; Williamson, Robert Anthony ; Giaccone, Giorgio ; Tagliavini, Fabrizio. / Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. In: Neurobiology of Disease. 2006 ; Vol. 23, No. 3. pp. 717-724.
@article{b93ecc534aee42928bb1b594323d0550,
title = "Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody",
abstract = "Prion diseases are characterized by the accumulation in the brain of abnormal conformers (PrPSc) of the cellular prion protein (PrPC). PrPSc immunohistochemistry, currently based on antibodies non-distinguishing between PrPC and PrPSc, requires pre-treatments of histological sections to eliminate PrPC and to denature PrPSc. We employed the PrPSc-specific antibody 89-112 PrP motif-grafted IgG on mildly fixed, untreated brain sections from several cases of human prion diseases. The results confirmed specific binding of IgG 89-112 to a structural determinant found exclusively on native disease-associated PrP conformations and lost following tissue denaturation or cross-linking fixation. Importantly, IgG 89-112 demonstrated no reactivity with normal brain tissue or with amyloid deposits in Alzheimer disease brain sections. Thus, immunohistochemical detection of native PrPSc deposits was obtained by means of a PrPSc-specific antibody. Such unique reagent may have many applications in the study of prion biology and in the diagnosis and prevention of prion diseases.",
author = "Gianluca Moroncini and Michela Mangieri and Michela Morbin and Giulia Mazzoleni and Bernardino Ghetti and Armando Gabrielli and Williamson, {Robert Anthony} and Giorgio Giaccone and Fabrizio Tagliavini",
year = "2006",
month = "9",
doi = "10.1016/j.nbd.2006.06.008",
language = "English",
volume = "23",
pages = "717--724",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody

AU - Moroncini, Gianluca

AU - Mangieri, Michela

AU - Morbin, Michela

AU - Mazzoleni, Giulia

AU - Ghetti, Bernardino

AU - Gabrielli, Armando

AU - Williamson, Robert Anthony

AU - Giaccone, Giorgio

AU - Tagliavini, Fabrizio

PY - 2006/9

Y1 - 2006/9

N2 - Prion diseases are characterized by the accumulation in the brain of abnormal conformers (PrPSc) of the cellular prion protein (PrPC). PrPSc immunohistochemistry, currently based on antibodies non-distinguishing between PrPC and PrPSc, requires pre-treatments of histological sections to eliminate PrPC and to denature PrPSc. We employed the PrPSc-specific antibody 89-112 PrP motif-grafted IgG on mildly fixed, untreated brain sections from several cases of human prion diseases. The results confirmed specific binding of IgG 89-112 to a structural determinant found exclusively on native disease-associated PrP conformations and lost following tissue denaturation or cross-linking fixation. Importantly, IgG 89-112 demonstrated no reactivity with normal brain tissue or with amyloid deposits in Alzheimer disease brain sections. Thus, immunohistochemical detection of native PrPSc deposits was obtained by means of a PrPSc-specific antibody. Such unique reagent may have many applications in the study of prion biology and in the diagnosis and prevention of prion diseases.

AB - Prion diseases are characterized by the accumulation in the brain of abnormal conformers (PrPSc) of the cellular prion protein (PrPC). PrPSc immunohistochemistry, currently based on antibodies non-distinguishing between PrPC and PrPSc, requires pre-treatments of histological sections to eliminate PrPC and to denature PrPSc. We employed the PrPSc-specific antibody 89-112 PrP motif-grafted IgG on mildly fixed, untreated brain sections from several cases of human prion diseases. The results confirmed specific binding of IgG 89-112 to a structural determinant found exclusively on native disease-associated PrP conformations and lost following tissue denaturation or cross-linking fixation. Importantly, IgG 89-112 demonstrated no reactivity with normal brain tissue or with amyloid deposits in Alzheimer disease brain sections. Thus, immunohistochemical detection of native PrPSc deposits was obtained by means of a PrPSc-specific antibody. Such unique reagent may have many applications in the study of prion biology and in the diagnosis and prevention of prion diseases.

UR - http://www.scopus.com/inward/record.url?scp=33747192871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747192871&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2006.06.008

DO - 10.1016/j.nbd.2006.06.008

M3 - Article

C2 - 16876426

AN - SCOPUS:33747192871

VL - 23

SP - 717

EP - 724

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

IS - 3

ER -